Deals of the Week: Allergan/MAP, Actavis/Uteron, Baxter/Ipsen, and More
Allergan’s buyout of MAP Pharma is an unusual case of a deal centered on drug under the shadow of a “complete response” letter, but it’s not the only one. How does it compare to recent precedents.
You may also be interested in...
The French pharma is the latest company to move its researchers closer to the center of vibrant academic and medical research in Cambridge, Mass.
Dutch start-up Dezima Pharma raises $18.6 million in Series A funding and government loans to move a next-generation CETP inhibitor to Phase III.
Biogen brings Tysabri fully in-house by using off-shore cash to compensate Irish partner Elan. Plus, the week in biopharma deal-making.